Nifurtimox/eflornithine
combination drug
Nifurtimox/eflornithine is a combination of two antiparasitic drugs, nifurtimox and eflornithine, used in the treatment of African trypanosomiasis (sleeping sickness). It was developed by Drugs for Neglected Diseases initiative and partners and is included in the World Health Organization's Model List of Essential Medicines. It is distributed in a kit with material to treat four patients, which weighs 39 kg and has a volume of 170 dm3, making the transport to remote rural hospitals a logistical challenge.
A treatment regimen known as nifurtimox-eflornithine combination treatment (NECT) is used in second stage gambiense African trypanosomiasis throughout Africa where the disease is endemic. The regimen involves slow infusion of 400 mg of eflornithine every 12 hours for 7 days combined with 15 mg/kg of nifurtimox orally three times a day for 10 days. The World Health Organization 2019 guidelines still recommend NECT in cases of advanced disease, but otherwise advise the use of fexinidazole.
“Nifurtimox/eflornithine” enters the record as combination drug. Crown Archives preserves that source wording while asking what Nifurtimox, eflornithine and combination can confirm, complicate or overturn.
Why this record matters
“Nifurtimox/eflornithine” is worth following because a concise public description often conceals a longer documentary argument. Here, Nifurtimox, eflornithine and combination provides the most credible route into that argument.
The citation trail is more important than the brevity of the summary: it shows where individual claims can be examined in context. The source revision retrieved here is dated Sep 20, 2026. The linked authority identifier is Q55239199. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2019.
Overview language is designed for orientation and should not be treated as a substitute for the evidence cited beneath it. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.
- Subject orientation
- Search vocabulary
- Locating named sources
The closest primary source, responsible institution and strongest cited specialist reference.
Three-step research path
- Establish the record: confirm the title “Nifurtimox/eflornithine”, its source revision and the description used here.
- Expand the search: follow Nifurtimox/eflornithine primary sources, Nifurtimox/eflornithine archive and Nifurtimox research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Nifurtimox/eflornithine”?
- What terminology or title could unlock a more precise catalogue search?
- Which institution is responsible for the underlying evidence?
Search terms from this dossier
This entry incorporates text from “Nifurtimox/eflornithine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.